Immunovant's experimental eye drug failed to meet primary endpoints in Phase 3 clinical studies, dealing a significant blow to the company's development program. The treatment, designed for an undisclosed ocular indication, was unable to demonstrate efficacy in the late-stage trials, according to BioPharma Dive.
Shares of Immunovant fell this week following the clinical trial disappointment. The company joins Alto and Oric Pharmaceuticals in experiencing stock declines tied to unfavorable clinical trial updates, highlighting the inherent risks in biotech investing.